Skip to content

How caffeine affects the visual brain

Effect of caffeine on visual neuroplasticity in young healthy adults

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12620000352909
Enrollment
20
Registered
2020-03-12
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Caffeine is readily available and widely consumed by adults of all ages. We are interested in whether temporarily manipulating caffeine levels (from complete washout to a controlled dose of caffeine) has an effect on ocular dominance in healthy adults. Specifically, we are testing its effect on a vision test that is frequently used to indirectly measure changes in brain function. If caffeine indeed influences our test results, then future studies may need to control caffeine consumption.

Interventions

Twenty healthy young (18-35 years) adults will be recruited and screened to ensure healthy eyes and vision. The screening includes a visual acuity test, determination of spectacle prescription, and brief ocular health examination. The main task is a measure of ocular dominance, where observers will look at patterns on a computer monitor and make judgments (by pressing a button) about the colour of a pattern that alternates between red and green. Both eyes need to be open (blinking allowed) duri

Twenty healthy young (18-35 years) adults will be recruited and screened to ensure healthy eyes and vision. The screening includes a visual acuity test, determination of spectacle prescription, and brief ocular health examination. The main task is a measure of ocular dominance, where observers will look at patterns on a computer monitor and make judgments (by pressing a button) about the colour of a pattern that alternates between red and green. Both eyes need to be open (blinking allowed) during the main task for ocular dominance to be measured. There will be two test sessions, a treatment session and control session. The order of the sessions will be randomised and the participants blinded to the treatment. Participants will be instructed not to consume caffeine for 12 hours prior to attending each test session. At the beginning of each test session, participants will undergo baseline testing of the main ocular dominance task (15 minutes). This will be followed by: (1) a controlled dose of caffeine in the form of a single ‘No Doz Plus’ pill, which consists of 100 mg caffeine, 10 mg thiamine hydrochloride (Vitamin B1) and 10 mg nicotinic acid (Vitamin B3), or (2) a placebo pill (single ‘Betamin’ pill, which consists of 100 mg thiamine hydrochloride (Vitamin B1). Participants will wait 30 minutes for the pill to reach its peak effect, and then the participant's dominant eye will be patched for 90 minutes. Post-patching ocular dominance tests (repeat of baseline tests, 15 minutes) will be conducted at the end of the session. During the 120 minutes of waiting, participants will be asked to sit quietly in a room and can undertake activities such as reading, watching a movie, or working on a laptop. At the second visit at least one week later, participants will undergo the same protocol (caffeine washout, baseline ocular dominance testing, tablet ingestion, patching of dominant eye, post-tablet ocular dominance testing) such that all participants will have consumed both the caffeine pill and placebo pill. The pills are both white, uncoated, round tablets with no engravings of approximately the same size, which will assist in masking the identity of the pill at each test session.

Sponsors

The University of Melbourne
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

1) Visual acuity at least 6/7.5 in both eyes 2) Good general health

Exclusion criteria

1) Contraindications for No Doz consumption: high blood pressure, recent heart attack, abnormal heart rhythm, stomach ulcer, inflamed colon and small intestine, severe liver disease, seizures, chronic insomnia, moderate to severe kidney impairment 2) Medications with possible interactions with No Doz and/or Vitamin B: tizanidine (muscle relaxant), digoxin (used to treat heart conditions), diuretics (particularly loop diuretics like furosemide), and phenytoin (used to treat epilepsy).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026